

18th DIA Japan Annual Meeting 2021

Application of Computational Modeling and Simulation
for Medical Devices; Topics from the PMDA report
数値シミュレーションの医療機器開発への応用;
PMDA科学委員会報告書から

CHINZEI Kiyoyuki, Ph.D.
Convenor, PMDA WG /
AIST, Japan



Disclaimer

- ▶ The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to DIA, its directors, officers, employees, volunteers, members, chapters, councils, Communities or affiliates, or any organization with which the presenter is employed or affiliated.
- ▶ These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. DIA and the DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners.

PMDA Science Board Report on CM&S


- ▶ Published March 2021
- ▶ Not intended to be a mandatory document
- ▶ Scope
 - How **emerging CM&S** applied to medical devices?
 - CM&S as a medical device
 - CM&S for a part of device evaluation
 - What **CM&S factors** impact in regulatory science?
 - How far **CM&S will change medical devices**?

<https://www.pmda.go.jp/files/000240657.pdf>
(in Japanese)



CM&S as a Medical Device

► Examples

- FFR_{CT} (Fractional Flow Reserve)
- Radiation dose simulator



► Errors directly impact patient efficacy / safety.



CM&S impacts for Regulatory Science

- ▶ What extent **interpolation & extrapolation** of CM&S applicable?
- ▶ What extent **uncertainties in CM&S** impact?
- ▶ CM&S to validate experiment?
- ▶ How can we use **digital evidence** in medical device evaluation?
- ▶ CM&S in machine learning: **Surrogate model?**


How we assess the credibility of CM&S?

Uncertainty Quantification (UQ)

Credibility of CM&S

- ▶ Equations (model) credibility
 - Theoretically deduced?
 - Experimentally fitted?
- ▶ Input/evidence credibility
 - Directly obtained from subject in focus?
 - Indirectly obtained from surrogate subject?

←
←
←
Uncertainty of
model & evidence



Model / Evidence Matrix

		Deductive model	Experimental model
	<i>Examples</i>	<i>Diffusion equation</i>	<i>Least square fitting</i>
Direct evidence	<ul style="list-style-type: none">- <i>Bone shape of the patient by CT</i>	A	B
Indirect evidence	<ul style="list-style-type: none">- <i>Mechanical property of aneurism from cadaver</i>- <i>Electrophysiological behavior of heart cell in vitro</i>	C	D



Interpolation & extrapolation

- A) Extrapolation may be discussed quantitatively.
 - Reduced N of evidence?
- B) Extrapolation can be discussed if stability of simulation demonstrated and agrees evidence.
- C) Extrapolation might be discussed.
- D) Extrapolation might be discussed but limited to subjectively.
 - Clinical validity may be discussed.

Provided affecting factors are also known & predictable.

	Deductive model	Experimental model
Direct evidence	A	B
Indirect evidence	C	D

Digital evidence, surrogate model

- ▶ As a tool to discuss credibility of experiment
 - Sensitivity against disturbance.
- ▶ CM&S with machine learning
 - CM&S → ML: reinforcement learning to add learning
 - ML → CM&S: surrogate model to reduce computation
- ▶ Regulatory science should prepare for such uses of CM&S

